Cagrilintide

Key Benefits#

• ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
• Synergistic appetite suppression complementing GLP-1 receptor agonists
• Reduces post-meal glucagon excursions improving glycemic control
• Slows gastric emptying contributing to prolonged satiety
• Once-weekly dosing via subcutaneous injection
• Potential for greater weight loss than semaglutide monotherapy

Mechanism of Action#

Cagrilintide binds amylin receptors (CALCR + RAMP1/2/3 complexes) in the area postrema and nucleus tractus solitarius. This slows gastric emptying, reduces post-meal glucagon secretion, and signals satiety to the hypothalamus. The combination with GLP-1 agonists produces synergistic weight loss beyond either agent alone, as the two compounds act on complementary satiety pathways.

Dosing Protocols#

Side Effects#

• Nausea (most common, especially during titration)
• Vomiting
• Decreased appetite
• Diarrhea
• Injection site reactions
• Hypoglycemia risk when combined with insulin secretagogues

Contraindications#

Personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Not FDA approved — investigational use only. Pregnancy and breastfeeding.

Storage#

Refrigerate at 2–8°C. Do not freeze. Protect from light.

1. 1.
   Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes

   Bailey CJ, Flatt PR, Conlon JM · Peptides · 2026ReviewPubMed Verified

2. 2.
   In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research

   Alhalabi H, Borschel L, Le Foll C, Thomas A, Bally L, Thevis M · Journal of pharmaceutical and biomedical analysis · 2026PubMed Verified

3. 3.
   Bariatric Surgery in the Era of GLP1RA: A Narrative Review

   Muhundan M, Dash S · Advances in therapy · 2026ReviewPubMed Verified

4. 4.
   Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity

   Chung CW, Kim J · Journal of obesity & metabolic syndrome · 2026ReviewPubMed Verified

5. 5.
   Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed

   Martínez-Castelao A, Górriz JL, Fernández-Fernández B, Soler MJ, Navarro-González JF · Journal of clinical medicine · 2025ReviewPubMed Verified

6. 6.
   Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies

   Rejili M, Hussain MS, Khan Y, Haouala F, Ganesan S, Sahoo S et al. · Vascular pharmacology · 2025ReviewPubMed Verified

7. 7.
   Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy

   Mehta M, Rometo D, Gusenoff J, Rubin JP · Plastic and reconstructive surgery · 2025PubMed Verified

8. 8.
   CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1

   Verma S, Böttcher M, Brown P, Dicker D, Rubino D, Sbraccia P et al. · Hypertension (Dallas, Tex. : 1979) · 2026RCTPubMed Verified

9. 9.
   Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply

   Davies MJ, Broholm C, Garvey WT · The New England journal of medicine · 2025PubMed Verified

10. 10.
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply

    Garvey WT, Osorto Contreras CK, Davies MJ · The New England journal of medicine · 2025PubMed Verified

11. 11.
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity

    Chi H, Yang H, Deng Y · The New England journal of medicine · 2025PubMed Verified

12. 12.
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity

    Lnu V, Noor F · The New England journal of medicine · 2025PubMed Verified

13. 13.
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity

    Krakauer JC, Krakauer NY · The New England journal of medicine · 2025PubMed Verified

14. 14.
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity

    Fogacci F, Cicero AFG · The New England journal of medicine · 2025PubMed Verified

15. 15.
    Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes

    Al-Harbi FA, Alsaif AK, Almutairi AG, Alshehri HJ, Aleidan EA, Alabdulaaly GS et al. · Metabolism open · 2025PubMed Verified

16. 16.
    Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?

    Muskiet MHA, Nardone M, Rensen PCN, Cherney DZI, Cooper ME · Lancet (London, England) · 2026ReviewPubMed Verified

17. 17.
    Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials

    Li C, Lin C, Cai X, Lv F, Yang W, Ji L · Obesity (Silver Spring, Md.) · 2025ReviewPubMed Verified

18. 18.
    Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

    Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T et al. · Molecular metabolism · 2025RCTPubMed Verified

19. 19.
    Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity

    Son JW, le Roux CW, Blüher M, Nauck MA, Lim S · Endocrine reviews · 2025PubMed Verified

20. 20.
    In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk

    Agarwal A, Padwal R, ACP Journal Club Editorial Team at McMaster University · Annals of internal medicine · 2025PubMed Verified

21. 21.
    Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials

    El-Sheikh M, Sillassen CDB, Wisborg FD, Hove JD, Dirksen C, Lee MMY et al. · BMJ open · 2025PubMed Verified

22. 22.
    Weight management treatment in obesity

    Rubio-Herrera MA, Mera-Carreiro S · Medicina clinica · 2025ReviewPubMed Verified

23. 23.
    Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors

    Gu YM, Yuan QN, Li X, He Q, Xu HE, Zhao LH · Acta pharmacologica Sinica · 2026PubMed Verified

24. 24.
    CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure

    Jacobsen JM, Halling JF, Blom I, Moreno Martinez J, Hald B, Pedersen K et al. · Nature metabolism · 2025PubMed Verified

25. 25.
    Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide

    Gabery S, Glendorf T, Ballarin-Gonzalez B, Pedersen K, Kruse T, Raun K et al. · Life sciences · 2025PubMed Verified

26. 26.
    Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3

    Carvas AO, Leuthardt A, Kulka P, Lommi G, Hassan S, Coester B et al. · EBioMedicine · 2025PubMed Verified

27. 27.
    Incretin-based therapies for the treatment of obesity-related diseases

    Caruso I, Cignarelli A, Sorice GP, Perrini S, Giorgino F · npj metabolic health and disease · 2024ReviewPubMed Verified

28. 28.
    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

    Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH et al. · The New England journal of medicine · 2025RCTPubMed Verified

29. 29.
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW et al. · The New England journal of medicine · 2025RCTPubMed Verified

30. 30.
    The Obesity Paradox of Cardiovascular Outcomes in Patients with Diabetes Mellitus

    Thakker J, Khaliq I, Ardeshna NS, Lavie CJ, Oktay AA · Current diabetes reports · 2025ReviewPubMed Verified

31. 31.
    Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review

    Al Lawati A, Alhabsi A, Rahul R, Savino ML, Alwahaibi H, Das S et al. · Diseases (Basel, Switzerland) · 2025ReviewPubMed Verified

32. 32.
    Advancing Diabetes Management and Glycemic Control While Exploring CagriSema's Impact on Obesity Management

    Hadid S, Frishman WH, Aronow WS · Cardiology in review · 2025PubMed Verified

33. 33.
    Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review

    Patel JP, Hardaswani D, Patel J, Saiyed F, Goswami RJ, Saiyed TI et al. · Cureus · 2025ReviewPubMed Verified

34. 34.
    Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors

    Cao J, Belousoff MJ, Johnson RM, Keov P, Mariam Z, Deganutti G et al. · Nature communications · 2025PubMed Verified

35. 35.
    Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities

    Bailey CJ, Flatt PR, Conlon JM · Peptides · 2025ReviewPubMed Verified

36. 36.
    The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines

    Madsbad S, Holst JJ · Expert opinion on investigational drugs · 2025ReviewPubMed Verified

37. 37.
    A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance

    Ludwig MQ, Coester B, Gordian D, Hassan S, Tomlinson AJ, Toure MH et al. · bioRxiv : the preprint server for biology · 2025PubMed Verified

38. 38.
    Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article

    Sidrak WR, Kalra S, Kalhan A · Indian journal of endocrinology and metabolism · 2024ReviewPubMed Verified

39. 39.
    Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis

    Dutta D, Nagendra L, Harish BG, Sharma M, Joshi A, Hathur B et al. · Indian journal of endocrinology and metabolism · 2024ReviewPubMed Verified

40. 40.
    Central nervous system pathways targeted by amylin in the regulation of food intake

    Hankir MK, Le Foll C · Biochimie · 2025ReviewPubMed Verified

41. 41.
    Amylin analogs for the treatment of obesity without diabetes: present and future

    Panou T, Gouveri E, Popovic DS, Papanas N · Expert review of clinical pharmacology · 2024ReviewPubMed Verified

42. 42.
    Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants

    Gabe MBN, Fuhr R, Sinn A, Eliasen A, Berthelsen KK, Kuhlman AB et al. · Diabetes, obesity & metabolism · 2024RCTPubMed Verified

43. 43.
    Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?

    Gogineni P, Melson E, Papamargaritis D, Davies M · Expert opinion on pharmacotherapy · 2024ReviewPubMed Verified

44. 44.
    Advancements in the management of obesity: a review of current evidence and emerging therapies

    Abdalla Ahmed MA, Ssemmondo E, Mark-Wagstaff C, Sathyapalan T · Expert review of endocrinology & metabolism · 2024ReviewPubMed Verified

45. 45.
    Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy

    Sun X, Yang D, Li Y, Shi J, Zhang X, Yi T · Peptides · 2024PubMed Verified

46. 46.
    Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity

    Eržen S, Tonin G, Jurišić Eržen D, Klen J · International journal of molecular sciences · 2024ReviewPubMed Verified

47. 47.
    Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

    Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY et al. · BMJ (Clinical research ed.) · 2024Meta-AnalysisPubMed Verified

48. 48.
    Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis

    Li H, Yu G, Huang Q, Yang B, Nie J, Liu Y et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Meta-AnalysisPubMed Verified

49. 49.
    Recent advances in peptide-based therapies for obesity and type 2 diabetes

    Bailey CJ, Flatt PR, Conlon JM · Peptides · 2024PubMed Verified

50. 50.
    Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review

    De R, Prasad F, Stogios N, Burin L, Ebdrup BH, Knop FK et al. · Expert opinion on pharmacotherapy · 2023ReviewPubMed Verified